Ezetimibe is a medication that is commonly used to lower cholesterol levels in the body. It works by inhibiting the absorption of cholesterol from the intestines, thereby reducing the amount of cholesterol that enters the bloodstream [1].

Vascepa, on the other hand, is a prescription omega-3 fatty acid medication that is used to reduce triglyceride levels in the blood. It is often prescribed to individuals with high triglyceride levels who are at risk of cardiovascular events [2].

While there is no direct information available on how ezetimibe enhances Vascepa's effects, it is important to note that both medications work in different ways to target different aspects of lipid metabolism.

Ezetimibe primarily focuses on reducing the absorption of cholesterol from the intestines, which helps to lower overall cholesterol levels in the body [1]. Vascepa, on the other hand, primarily targets triglyceride levels in the blood [2].

Since ezetimibe primarily reduces cholesterol absorption, it may indirectly enhance the effects of Vascepa by further reducing the amount of cholesterol that enters the bloodstream. This could potentially lead to a greater reduction in triglyceride levels, as cholesterol and triglycerides are closely linked in the body's lipid metabolism [3].

However, it is important to note that the specific interaction between ezetimibe and Vascepa has not been extensively studied or documented in the available sources. Therefore, it is recommended to consult with a healthcare professional for more detailed information and guidance on the potential benefits and risks of combining these medications.

In conclusion, while the exact mechanism of how ezetimibe enhances Vascepa's effects is not clear, it is possible that ezetimibe's ability to reduce cholesterol absorption may indirectly contribute to a greater reduction in triglyceride levels when used in combination with Vascepa. However, further research and clinical studies are needed to fully understand the potential synergistic effects of these medications.

Sources:
[1] DrugPatentWatch. (n.d.). Ezetimibe - Tradename: Ezetimibe. Retrieved from https://www.drugpatentwatch.com/p/tradename/EZETIMIBE
[2] Mayo Clinic. (2021). Cholesterol medications: Consider the options. Retrieved from https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/cholesterol-medications/art-20050958
[3] Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., & Braeckman, R. A. (2015). Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis, 242(1), 87-94. doi: 10.1016/j.atherosclerosis.2015.06.052. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671468/